Diabeloop, a company focused on collective intelligence
“At Diabeloop, there are 2 core elements that motivate people on a daily-basis. The first one is teamwork. We feel great pride when we work together to accomplish challenging goals. The second one is about seeing our impact on people living with Type 1 diabetes. When they say: “It’s extraordinary, you have changed my life”, it gives us pride, energy and motivation to continue. That is why we get up every morning!” – Erik Huneker, co-founder and CEO of Diabeloop.
The international ambition of a diabetes medtech
In November 2018, Diabeloop’s first medical device, the DBLG1, obtained CE marking, a marketing authorization for most of Europe.
In 2019, the company submitted the DBLG1 System to French reimbursement agreement.
In Germany, a market particularly interested by new technologies, Diabeloop is in the midst of conversations with health insurers.
In the medium term, we are planning a progressive commercial launch in a majority of European countries.

Our ecosystem
A trio for complementary management
Erik Huneker, an engineer who graduated from the Ecole Polytechnique, is a tech and science enthusiast, and had been working in the medical device industry. In 2015, he founded Diabeloop with Dr. Guillaume Charpentier, a diabetologist and Chief Medical Officer of the company. Since 2016, he co-manages Diabeloop with Marc Julien, who graduated from INSEAD and has over 25 years of experience in consulting, investment and entrepreneurship.

Diabeloop’s board members
Diabeloop’s board includes…
The management of Diabeloop:
- Dr. Guillaume Charpentier, founder, Chief Medical Officer and President of the board
- Erik Huneker, co-founder and CEO
- Marc Julien, co-CEO
And its largest investors:
- Aymar Henin
- Catherine Dunand (CEMAG INVEST)
- Celia Hart (Supernova Invest)
- François Miceli (Sofimac Innovation)
- Olivier Boucat (ALIAD Venture Capital, by Air Liquide)

Diabeloop Supporters







